Skip to contentHome page Seeking Alpha - Power to InvestorsWeight LossOct 29, 2026, 1:20 AM ETVanEck Pharmaceutical ETF (PPH)IHE, PJPWilson Research643 FollowersSummaryVanEck Pharmaceutical ETF is upgraded to Buy, driven by innovation in weight-loss treatments and robust product pipelines among top holdings.PPH's concentrated exposure to Eli Lilly, Merck, and Novo Nordisk provides key catalysts, with LLY's 49% revenue growth and novel obesity drugs leading the charge.Despite industry risks—pricing pressure, patent cliffs, and high R&D costs—PPH's top holdings are mitigating these through diversification and strong product pipelines.PPH offers a higher dividend yield (1.87%) and lower expense ratio than peers, with current catalysts expected to deliver competitive returns versus the broader market.kemalbas/iStock via Getty ImagesInvestment ThesisVanEck Pharmaceutical ETF (PPH) warrants a Buy rating due to its current mix of pharmaceutical companies that are seeing key catalysts for growth. These factors include innovation in weight-loss treatments, a high quantity ofThis article was written byWilson Research643 FollowersWilson Research seeks to provide investors with focused insights on predominantly exchange-traded funds, or ETFs, with a blend between growth potential and dividend yield. The analysis provided emphasizes fundamental analysis while including macro-level factors such as industry trends, economics, geopolitics, and a variety of other influential factors. Wilson Reseach includes an MBA graduate and independent financial coach who seek to provide actionable information for long-term investors who value diversification while keeping their fees as low as possible. Wilson Research is inspired by the investment philosophies of Warren Buffett and the entrepreneurial philosophies of Robert Kiyosaki.Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.This article is exclusive to Seeking Alpha. No duplication or reproduction of this article is allowed without consent of Seeking Alpha and the author. This article should not be misconstrued as individual financial advice. Always conduct your own due diligence prior to investing.Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.CommentsTo ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.Is this happening to you frequently? Please report it on our feedback forum.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.